Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Supernus Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, cash flow, and acquistions and subsidiaries.

Stock Price



Market Capitalization

$1.6 B



$667.2 M

FY, 2022

CreditSafe Score

Score changed on May 19, 2024
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn more

Financial Statements

USDFY, 2016FY, 2020FY, 2021FY, 2022
Revenue growth, %48.9%
Cost of goods sold12.0M52.5M75.1M
Gross profit198.1M467.9M504.7M
Gross profit margin, %94.3%89.9%87.1%
General and administrative expense106.0M200.7M304.8M377.2M
Operating expense total143.9M294.2M395.2M451.8M
Depreciation and amortization15.7M
EBIT margin, %25.8%33.4%14.8%6.9%
Interest income1.5M18.7M
Interest expense3.8M23.4M
Pre tax profit50.4M168.6M73.2M60.7M
Income tax expense(40.9M)41.7M19.8M32.0K
Net Income91.2M127.0M53.4M60.7M

Acquisitions & Subsidiaries

Company nameDateDeal size
LoremDec 23, 2021$40.0M
IpsumJan 18, 2022$30.0M
Lorem IpsumFeb 18, 2022$25.0M
DolorOct 21, 2021$60.0M
Premium Content only available in Craft’s Intelligence Portal
View acquisitions and subsidiaries by company, date, and deal size.
Understanding this data enables better supplier & customer negotiations and helps identify potential opportunities or market risks for your firm.
Learn more

Footer menu